The Dual-Hormone Breakthrough in Type 1 Diabetes Care

By integrating glucagon—the physiological "antagonist" to insulin—into automated delivery systems, researchers have identified a way to create a chemical safety net that could revolutionize patient safety.

This moves us away from the hit-or-miss nature of current treatments toward a mathematically "perfect" dosing schedule.

The study used a sophisticated in-silico model of an average 78 kg adult to prove dual-hormone therapy is significantly more resilient.

In simulations of a 70g glucose meal:

• Dual-Hormone Therapy (ReMF): Achieved a Blood Glucose Index (BGI) Integral of 21.96, maintaining a tight range (99.0 mg/dL to 123.0 mg/dL).
• Insulin Monotherapy: Resulted in a BGI Integral of 105.17, with a wider, riskier range (92.85 mg/dL to 130.65 mg/dL).

The model defines the critical "when" for each hormone:

1. Insulin: Deliver a bolus roughly 30 minutes before a meal to crush the initial sugar spike.
2. Glucagon: Administer the optimal pulse approximately 90 minutes post-meal to arrest a potential crash.

This delay allows for more aggressive, effective insulin dosing with a built-in safety mechanism.

When tested against 100 perturbed systems to simulate real-world physical variations:

• Dual-Hormone Therapy maintained exceptional accuracy of 92–94% on the Control Variability Grid Analysis (CVGA).
• Standard Insulin Therapy managed a comparatively dismal accuracy of 37%.

The leap from math to the medicine cabinet remains complex. Important limitations include:

• Physiological Unknowns: The long-term effects of repeated glucagon use, such as hepatic glycogen depletion, are not yet accounted for.
• Patient Burden: The system still requires precise knowledge of meal timing and carbohydrate counts.
• Model vs. Reality: These are results from pristine digital simulations that must now bridge the gap to the unpredictable human body.